266 related articles for article (PubMed ID: 36298832)
1. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience.
Totschnig D; Augustin M; Niculescu I; Laferl H; Jansen-Skoupy S; Lehmann C; Wenisch C; Zoufaly A
Viruses; 2022 Oct; 14(10):. PubMed ID: 36298832
[TBL] [Abstract][Full Text] [Related]
2. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
[TBL] [Abstract][Full Text] [Related]
3. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis.
Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E
J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147
[TBL] [Abstract][Full Text] [Related]
5. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
Ustianowski A
Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
[TBL] [Abstract][Full Text] [Related]
7. Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
Schiaroli E; Gidari A; Brachelente G; Bicchieraro G; Spaccapelo R; Bastianelli S; Pierucci S; Busti C; Pallotto C; Malincarne L; Camilloni B; Falcinelli F; De Socio GV; Villa A; Mencacci A; Francisci D
J Clin Virol; 2023 Nov; 168():105584. PubMed ID: 37778220
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis.
Alhumaid S; Al Mutair A; Alali J; Al Dossary N; Albattat SH; Al HajjiMohammed SM; Almuaiweed FS; AlZaid MR; Alomran MJ; Alqurini ZS; Alsultan AA; Alhajji TS; Alshaikhnasir SM; Al Motared A; Al Mutared KM; Hajissa K; Rabaan AA
Diseases; 2022 Dec; 10(4):. PubMed ID: 36547204
[TBL] [Abstract][Full Text] [Related]
9. Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.
Kawashima I; Hyuga H; Nakadate A; Matsuura M; Sakamoto Y; Suzuki J; Kumagai T; Suzuki M; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kirito K
Int J Hematol; 2023 Dec; 118(6):731-736. PubMed ID: 37747583
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.
Soeroto AY; Yanto TA; Kurniawan A; Hariyanto TI
Rev Med Virol; 2023 Mar; 33(2):e2420. PubMed ID: 36617704
[TBL] [Abstract][Full Text] [Related]
11. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
12. Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era.
Gottlieb J; Simon S; Barton J; Barnikel M; Bachmann M; Klingenberg MS; Veit T; Kneidinger N
Infection; 2023 Oct; 51(5):1481-1489. PubMed ID: 36929650
[TBL] [Abstract][Full Text] [Related]
13. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis.
Al Jurdi A; El Mouhayyar C; Efe O; Jeyabalan A; Riella LV
J Nephrol; 2024 Jan; 37(1):141-147. PubMed ID: 37658973
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience.
Pulvirenti F; Garzi G; Milito C; Sculco E; Sciannamea M; Napoli A; Cinti L; Roberto P; Punziano A; Carrabba M; Piano Mortari E; Carsetti R; Antonelli G; Quinti I
Front Immunol; 2023; 14():1249462. PubMed ID: 37954618
[TBL] [Abstract][Full Text] [Related]
15. Tixagevimab-Cilgavimab Decreases the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients.
Sanayei AM; Montalvan A; Faria I; Ochalla J; Pavlakis M; Blair BM; Alonso CD; Curry M; Saberi B
Transplant Proc; 2023 Oct; 55(8):1784-1792. PubMed ID: 37661468
[TBL] [Abstract][Full Text] [Related]
16. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019.
Montastruc F; Lafaurie M; Flumian C; de Canecaude C
Clin Microbiol Infect; 2023 Apr; 29(4):543.e1-543.e3. PubMed ID: 36464214
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.
Thomas M; Masson M; Bitoun S; Hamroun S; Seror R; Dupuy H; Lazaro E; Richez C; Allanore Y; Avouac J
Rheumatology (Oxford); 2024 May; 63(6):1632-1638. PubMed ID: 37632774
[TBL] [Abstract][Full Text] [Related]
18. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of two anti-SARS-CoV-2 antibody immunoassays for monitoring patients on pre-exposure prophylaxis.
Vellas C; Dimeglio C; Joncour E; Staes L; Jamme T; Miedougé M; Da-Silva I; Porcheron M; Migueres M; Kamar N; Izopet J
Diagn Microbiol Infect Dis; 2023 Dec; 107(4):116071. PubMed ID: 37716217
[TBL] [Abstract][Full Text] [Related]
20. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]